AptaC – Aptamers and fusion aptamers binding haemostatic molecules for diagnostic and therapeutic use
Activated protein C (APC) plays a key role in vascular and inflammatory diseases. As endogenous inhibitor APC inactivates blood clotting factors Va and VIIIa controlling plasmatic haemostasis.
The inventions provide aptamers as diagnostic tools for detection of APC in biological samples also in the presence of abundant inactive protein C with high selective specificity. This allows establishment of routine diagnostics for APC to analyse disturbances in haemostasis, e.g. in sepsis or in haemophilia A. Further the inventions provide therapeutic aptamers binding to APC for the control of bleeding events, e.g. in haemophilia A or Willebrand syndrome.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…
